DeepMed Research

Yuhan Corporation

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Clinical Trial to Assess the Effect of Food on the Pharmacokinetics of YHD1119 in Healthy Volunteers

Phase 1

Completed

Conditions: Peripheral Neuropathic Pain

Interventions: Drug: YHD1119 300mg

First Posted Date: 2017-06-19

Last Posted Date: 2019-01-16

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 24

Registration Number: NCT03191136

Locations: 🇰🇷
Chonbuk National University Hospital, Jeonju, Korea, Republic of

Clinical Trial to Compare the Safety and Pharmacokinetics of YHP1604 in Comparison to the Co-administration of Telmisartan/Amlodipine and Rosuvastatin

Phase 1

Completed

Conditions: Hypertension
Hyperlipidemia

Interventions: Drug: Temisartan/Amlodipine+Rosuvastatin
Drug: YHP1604

First Posted Date: 2017-04-17

Last Posted Date: 2019-01-16

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 62

Registration Number: NCT03116516

Locations: 🇰🇷
Chonbuk National University Hospital, Jeonju, Korea, Republic of

Clinical Trial to Evaluate the Efficacy and Safety of YHP1701

Phase 3

Completed

Conditions: Hypertension and Hyperlipidemia

Interventions: Drug: YHR1703
Drug: YHR1704
Drug: YHP1701

First Posted Date: 2017-04-06

Last Posted Date: 2018-09-07

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 106

Registration Number: NCT03103256

Locations: 🇰🇷
Seoul Medical Center, Seoul, Korea, Republic of

Clinical Trial of Temisartan/Amlodipine & Rosuvastatin in Subjects With Hypertension and Hyperlipidemia

Phase 3

Completed

Conditions: Hypertension
Hyperlipidemia

Interventions: Drug: Temisartan+Rosuvastatin
Drug: Temisartan+Amlodipine+Rosuvastatin (Combination drug)
Drug: Temisartan+Amlodipine

First Posted Date: 2017-03-01

Last Posted Date: 2019-01-16

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 202

Registration Number: NCT03067688

Locations: 🇰🇷
Seoul Natuional University Hospital, Seoul, Jongno, Korea, Republic of

Clinical Trial of YH25448 in Patients with EGFR Mutation Positive Advanced NSCLC

Phase 1

Completed

Conditions: EGFR Gene Mutation

Interventions: Drug: YH25448

First Posted Date: 2017-02-08

Last Posted Date: 2025-03-21

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 224

Registration Number: NCT03046992

Locations: 🇰🇷
The Catholic University of Korea, Bucheon St. Mary's Hospital, Bucheon-si, Gyeonggi-do, Korea, Republic of
🇰🇷
CHA Bundang Medical Center, CHA University, Seongnam-si, Gyeonggi-do, Korea, Republic of
🇰🇷
Gachon University Gil Medical Center, Incheon, Korea, Republic of

and more 13 locations

Clinical Trial of YHD1119 in Patients With Peripheral Neuropathic Pain

Phase 3

Completed

Conditions: Peripheral Neuropathic Pain

Interventions: Drug: YHD1119
Drug: Lyrica

First Posted Date: 2016-12-07

Last Posted Date: 2019-01-16

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 371

Registration Number: NCT02985216

Locations: 🇰🇷
Yong Chul Kim, Seoul, Korea, Republic of

A Clinical Trial of YMC017 in Hypertensive and Hypercholesterolemic Patients With Metabolic Syndrome

Phase 4

Terminated

Conditions: Metabolic Syndrome

Interventions: Drug: Telmisartan 40mg, 80 mg
Drug: Telmisartan 40mg + Rosuvastatin 20mg
Drug: Rosuvastatin 20mg
Drug: Telmisartan 80mg + Rosuvastatin 20mg

First Posted Date: 2016-11-18

Last Posted Date: 2019-04-12

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 55

Registration Number: NCT02968160

Locations: 🇰🇷
Dongguk University Medical Center, Ilsan, Korea, Republic of

A Study to Investigate Pharmacokinetic Drug Interaction and Safety of Telmisartan/Amlodipine and Rosuvastatin

Phase 1

Completed

Conditions: Hypertension
Hyperlipidemia

Interventions: Drug: Twynsta 80/5mg
Drug: Crestor 20mg

First Posted Date: 2016-11-01

Last Posted Date: 2017-02-01

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 60

Registration Number: NCT02951962

Locations: 🇰🇷
Chonbuk National University Hospital, Chunju, Korea, Republic of

A Clinical Trial of YH1177 in Patients With Otitis Media and Otorrhea

Phase 1

Terminated

Conditions: Otitis Media
Otorrhea

Interventions: Drug: piperacillin 4% + tazobactam 0.5% + dexamethasone 0.1%
Drug: piperacillin 8% + tazobactam 1.0% + dexamethasone 0.1%
Drug: piperacillin 2% + tazobactam 0.25%
Drug: piperacillin 8% + tazobactam 1.0%
Drug: piperacillin 4% + tazobactam 0.5%

First Posted Date: 2016-06-29

Last Posted Date: 2022-01-13

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 135

Registration Number: NCT02817347

Locations: 🇰🇷
Chonnam National Universitiy Hospital, Gwangju, Chonnam, Korea, Republic of

A Open-label, Randomized, Crossover Study to Assess PK of Pregabalin

Phase 1

Completed

Conditions: Peripheral Nueropathy Pain

Interventions: Drug: YHD1119
Drug: Lyrica

First Posted Date: 2016-05-26

Last Posted Date: 2019-01-16

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 32

Registration Number: NCT02783183

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy